The importance of the tumor microenvironment in the therapeutic management of cancer

References

• Quatresooz P, Reginster MA, Pierard GE. ’Malignant melanoma microecosystem’: Immunohistopathological insights into the stromal cell phenotype. Exp Ther Med 2011;2(3):379-84
   Google Scholar
• Sun Y, Nelson PS. Molecular pathways: involving microenvironment damage responses in cancer therapy resistance. Clin Cancer Res 2012;18(15):4019-25
   PubMed Web of Science ®Google Scholar
• Lanca T, Silva-Santos B. The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. Oncoimmunology 2012;1(5):717-25
   PubMed Web of Science ®Google Scholar
• Ma J, Liu L, Che G, et al. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2010;10:112
   PubMed Web of Science ®Google Scholar
• Lan C, Huang X, Lin S, et al. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat 2013;12(3):259-67
   PubMed Web of Science ®Google Scholar
• Zhang B, Yao G, Zhang Y, et al. M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo) 2011;66(11):1879-86
   Google Scholar
• Hao NB, Lu MH, Fan YH, et al. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012;2012:948098
   PubMedGoogle Scholar
• Végran F, Apetoh L, Ghiringhelli F. Th9 cells: a novel CD4 T-cell subset in the immune war against cancer. Cancer Res 2015;75(3):475-9
   Google Scholar
• Wesolowski R, Markowitz J, Carson WE. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer 2013;1:10
   PubMedGoogle Scholar
• Arihara F, Mizukoshi E, Kitahara M, et al. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother 2013;62(8):1421-30
   PubMed Web of Science ®Google Scholar
• Gabitass RF, Annels NE, Stocken DD, et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011;60(10):1419-30
   PubMed Web of Science ®Google Scholar
• Nakasone ES, Askautrud HA, Kees T, et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012;21(4):488-503
   PubMed Web of Science ®Google Scholar
• Pinto A, Rega A, Crother TR, Sorrentino R. Plasmacytoid dendritic cells and their therapeutic activity in cancer. Oncoimmunology 2012;1(5):726-34
   PubMed Web of Science ®Google Scholar
• Bleotu C, Chifiriuc MC, Grigore R, et al. Investigation of Th1/Th2 cytokine profiles in patients with laryngo-pharyngeal, HPV-positive cancers. Eur Arch Otorhinolaryngol 2013;270(2):711-18
   Google Scholar
• Rucki AA, Zheng L. Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies. World J Gastroenterol 2014;20(9):2237-46
   PubMed Web of Science ®Google Scholar
• Annunziato F, Cosmi L, Liotta F, et al. Main features of human T helper 17 cells. Ann N Y Acad Sci 2013;1284:66-70
   PubMed Web of Science ®Google Scholar
• Lin X, Chen M, Liu Y, et al. Advances in distinguishing natural from induced Foxp3(+) regulatory T cells. Int J Clin Exp Pathol 2013;6(2):116-23
   PubMed Web of Science ®Google Scholar
• Ueha S, Yokochi S, Ishiwata Y, et al. Robust anti-tumor effects of combined anti-CD4 depleting antibody and anti-PD-1/PD-L1 immune checkpoint antibody treatment in mice. Cancer Immunol Res 2015;3(6):631-40
   Google Scholar
• Marabelle A, Kohrt H, Sagiv-Barfi I, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013;123(6):2447-63
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 2014;63(1):67-72.2014
   PubMed Web of Science ®Google Scholar
• Correale P, Rotundo MS, Del Vecchio MT, et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010;33(4):435-41
   PubMed Web of Science ®Google Scholar
• Jia Y, Zeng Z, Li Y, et al. Impaired function of CD4+ T follicular helper (Tfh) cells associated with hepatocellular carcinoma progression. PLoS One 2015;10(2):e0117458
   Web of Science ®Google Scholar
• Vantourout P, Hayday A. Six-of-the-best: unique contributions of gammadelta T cells to immunology. Nat Rev Immunol 2013;13(2):88-100
   PubMed Web of Science ®Google Scholar
• El-Shinawi M, Abdelwahab SF, Sobhy M, et al. Capturing and characterizing immune cells from breast tumor microenvironment: an innovative surgical approach. Ann Surg Oncol 2010;17(10):2677-84
   Google Scholar
• Motomura T, Shirabe K, Mano Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 2013;58(1):58-64
   PubMed Web of Science ®Google Scholar
• Grenz S, Naschberger E, Merkel S, et al. IFN-gamma-driven intratumoral microenvironment exhibits superior prognostic effect compared with an IFN-alpha-driven microenvironment in patients with colon carcinoma. Am J Pathol 2013;183(6)):1897-909
   Google Scholar
• Chew V, Chen J, Lee D, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 2012;61(3):427-38
   PubMed Web of Science ®Google Scholar
• Kaufman HL. Precision Immunology: The Promise of Immunotherapy for the Treatment of Cancer. J Clin Oncol 2015;33(12):1315-17
   PubMed Web of Science ®Google Scholar
• Woo SR, Corrales L, Gajewski TF. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol 2015;36(4):250-6
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14(10):1014-22
   PubMed Web of Science ®Google Scholar
• Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012;72(4):917-27
   PubMed Web of Science ®Google Scholar
• Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 2014;232(2):199-209
   PubMed Web of Science ®Google Scholar
• Benazzi C, Al-Dissi A, Chau CH, et al. Angiogenesis in spontaneous tumors and implications for comparative tumor biology. ScientificWorldJournal 2014;2014:919570
   Google Scholar
• Cao Z, Bao M, Miele L, et al. Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer 2013;49(18):3914-23
   PubMed Web of Science ®Google Scholar
• Cao Z, Shang B, Zhang G, et al. Tumor cell-mediated neovascularization and lymphangiogenesis contrive tumor progression and cancer metastasis. Biochim Biophys Acta 2013;1836(2):273-86
   Google Scholar
• Chen Y, Yan J, Yuan Z, et al. A meta-analysis of the relationship between lymphatic microvessel density and clinicopathological parameters in breast cancer. Bull Cancer 2013;100(3):1-10
   Google Scholar
• Wang J, Guo Y, Wang B, et al. Lymphatic microvessel density and vascular endothelial growth factor-C and -D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature. Mol Biol Rep 2012;39(12):11153-65
   PubMed Web of Science ®Google Scholar
• Cao W, Fan R, Yang W, Wu Y. VEGF-C expression is associated with the poor survival in gastric cancer tissue. Tumour Biol 2014;35(4):3377-83
   Google Scholar
• Quatresooz P, Piérard-Franchimont C, Noël F, Piérard GE. Thigmotropism of malignant melanoma cells. Dermatol Res Pract 2012;2012:362784
   Google Scholar
• Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21(3):309-22
   PubMed Web of Science ®Google Scholar
• Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci 2012;125(Pt 23):5591-6
   PubMed Web of Science ®Google Scholar
• Jia Z, Rahmatpanah FB, Chen X, et al. Expression changes in the stroma of prostate cancer predict subsequent relapse. PLoS One 2012;7(8):e41371
   Google Scholar
• Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121(3):335-48
   PubMed Web of Science ®Google Scholar
• Cooke VG, LeBleu VS, Keskin D, et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012;21(1):66-81
   PubMed Web of Science ®Google Scholar
• Suetsugu A, Hassanein MK, Reynoso J, et al. The cyan fluorescent protein nude mouse as a host for multicolor-coded imaging models of primary and metastatic tumor microenvironments. Anticancer Res 2012;32(1):31-8
   PubMed Web of Science ®Google Scholar
• Yamauchi K, Tome Y, Yamamoto N, et al. Color-coded real-time subcellular fluorescence imaging of the interaction between cancer and host cells in live mice. Anticancer Res 2012;32(1):39-43
   Google Scholar
• Gianotti L, Fortis C, Braga M, et al. Radical oncologic surgery affects the circulatory levels of interleukin 10. J Surg Oncol 1997;66(4):244-7
   Google Scholar
• Romano F, Piacentini MG, Franciosi C, et al. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients. Hepatogastroenterology 2004;51(60):1872-6
   Google Scholar
• Cesana GC, Romano F, Piacentini G, et al. Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis. Ann Surg Oncol 2007;14(4):1295-304
   Google Scholar
• Eveno C, Pocard M. VEGF levels and the angiogenic potential of the microenvironment can affect surgical strategy for colorectal liver metastasis. Cell Adh Migr 2012;6(6):569-73
   PubMed Web of Science ®Google Scholar
• Predina JD, Judy B, Fridlender ZG, et al. A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation. Cancer Biol Ther 2012;13(9):745-55
   PubMed Web of Science ®Google Scholar
• Pierard GE, Pierard-Franchimont C, Reginster MA, Quatresooz P. Smouldering malignant melanoma and metastatic dormancy: an update and review. Dermatol Res Pract 2012;2012:461278
   Google Scholar
• Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 2014;21(1):15-25
   PubMed Web of Science ®Google Scholar
• Dijkgraaf EM, Heusinkveld M, Tummers B, et al. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res 2013;73(8):2480-92
   PubMed Web of Science ®Google Scholar
• Obermajer N, Wong JL, Edwards RP, et al. PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol Invest 2012;41(6-7):635-57
   PubMed Web of Science ®Google Scholar
• Tsuchikawa T, Md MM, Yamamura Y, et al. The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma. Ann Surg Oncol 2012;19(5):1713-19
   Google Scholar
• Sevko A, Michels T, Vrohlings M, et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol 2013;190(5):2464-71
   PubMed Web of Science ®Google Scholar
• Affara NI, Ruffell B, Medler TR, et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell 2014;25(6):809-21
   PubMed Web of Science ®Google Scholar
• Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother 2013;62(2):203-16
   PubMed Web of Science ®Google Scholar
• Hale MD, Hayden JD, Grabsch HI. Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response. Cell Oncol (Dordr) 2013;36(2):95-112
   Google Scholar
• Efstathiou E, Troncoso P, Wen S, et al. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 2007;13(4):1224-31
   PubMed Web of Science ®Google Scholar
• Miyata K, Takagi S, Sato S, et al. Suppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragment. Cancer Med 2014;3(6):1595-604
   Google Scholar
• Accolla RS, Lombardo L, Abdallah R, et al. Boosting the MHC class ii-restricted tumor antigen presentation to CD4+ T helper cells: a critical issue for triggering protective immunity and re-orienting the tumor microenvironment toward an anti-tumor state. Front Oncol 2014;4:32
   Google Scholar
• Golden EB, Pellicciotta I, Demaria S, et al. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol 2012;2:88
   PubMedGoogle Scholar
• Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. J Clin Invest 2013;123(7):2756-63
   PubMed Web of Science ®Google Scholar
• Durante M, Reppingen N, Held KD. Immunologically augmented cancer treatment using modern radiotherapy. Trends Mol Med 2013;19(9):565-82
   PubMed Web of Science ®Google Scholar
• Qinfeng S, Depu W, Xiaofeng Y, et al. In situ observation of the effects of local irradiation on cytotoxic and regulatory T lymphocytes in cervical cancer tissue. Radiat Res 2013;179(5):584-9
   Google Scholar
• Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med 2015;212(4):435-45
   PubMed Web of Science ®Google Scholar
• Crittenden MR, Cottam B, Savage T, et al. Expression of NF-kappaB p50 in tumor stroma limits the control of tumors by radiation therapy. PLoS One 2012;7(6):e39295
   Google Scholar
• Kanagavelu S, Gupta S, Wu X, et al. In vivo effects of lattice radiation therapy on local and distant lung cancer: potential role of immunomodulation. Radiat Res 2014;182(2):149-62
   PubMed Web of Science ®Google Scholar
• Sierro SR, Donda A, Perret R, et al. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol 2011;41(8):2217-28
   PubMed Web of Science ®Google Scholar
• Wu CY, Yang LH, Yang HY, et al. Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res 2014;20(3):644-57
   Google Scholar
• Helbig L, Koi L, Bruchner K, et al. Hypoxia-inducible factor pathway inhibition resolves tumor hypoxia and improves local tumor control after single-dose irradiation. Int J Radiat Oncol Biol Phys 2014;88(1):159-66
   Google Scholar
• Stegeman H, Kaanders JH, Wheeler DL, et al. Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck. BMC Cancer 2012;12:463
   Google Scholar
• Chen FH, Fu SY, Yang YC, et al. Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway. Int J Radiat Oncol Biol Phys 2013;86(4):777-84
   Google Scholar
• Yoshimura M, Itasaka S, Harada H, Hiraoka M. Microenvironment and radiation therapy. Biomed Res Int 2013;2013:685308
   PubMed Web of Science ®Google Scholar
• Kuonen F, Secondini C, Ruegg C. Molecular pathways: emerging pathways mediating growth, invasion, and metastasis of tumors progressing in an irradiated microenvironment. Clin Cancer Res 2012;18(19):5196-202
   Google Scholar
• Wen FT, Thisted RA, Rowley DA, Schreiber H. A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. Oncoimmunology 2012;1(2):172-8
   PubMed Web of Science ®Google Scholar
• Sevko A, Sade-Feldman M, Kanterman J, et al. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol 2013;133(6):1610-19
   PubMed Web of Science ®Google Scholar
• Merelli B, Massi D, Cattaneo L, Mandalà M. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol 2014;89(1):140-65
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515(7528):568-71
   PubMed Web of Science ®Google Scholar
• Honeychurch J, Cheadle EJ, Dovedi SJ, Illidge TM. Immuno-regulatory antibodies for the treatment of cancer. Expert Opin Biol Ther 2015;15(6):787-801
   Google Scholar
• Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res 2015;75(1):5-10
   PubMed Web of Science ®Google Scholar
• Hosoi A, Matsushita H, Shimizu K, et al. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells. Int J Cancer 2014;134(8):1810-22
   Google Scholar
• Aida K, Miyakawa R, Suzuki K, et al. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-alpha gene therapy for pancreatic cancer. Cancer Sci 2014;105(2):159-67
   PubMed Web of Science ®Google Scholar
• Izzi V, Buler M, Masuelli L, et al. Poxvirus-based vaccines for cancer immunotherapy: new insights from combined cytokines/co-stimulatory molecules delivery and “uncommon” strains. Anticancer Agents Med Chem 2014;14(2):183-9
   Google Scholar
• Bovenberg MS, Degeling MH, Tannous BA. Cell-based immunotherapy against gliomas: from bench to bedside. Mol Ther 2013;21(7):1297-305
   Google Scholar
• Ogi C, Aruga A. Immunological monitoring of anticancer vaccines in clinical trials. Oncoimmunology 2013;2(8):e26012
   PubMed Web of Science ®Google Scholar
• Predina J, Eruslanov E, Judy B, et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci USA 2013;110(5):E415-24
   PubMedGoogle Scholar